Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer

Michael Kloth; Vanessa Ruesseler; Christoph Engel; Katharina Koenig; Martin Peifer; Erika Mariotti; Helen Kuenstlinger; Alexandra Florin; Ursula Rommerscheidt-Fuss; Ulrike Koitzsch; Claudia Wodtke; Frank Ueckeroth; Stefanie Holzapfel; Stefan Aretz; Peter Propping; Markus Loeffler; Sabine Merkelbach-Bruse; Margarete Odenthal; Nicolaus Friedrichs; Lukas Carl Heukamp; Thomas Zander; Reinhard Buettner

doi:10.1136/gutjnl-2014-309026

Article info

Colon

Original article

Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer

Authors

Michael Kloth Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Vanessa Ruesseler Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Christoph Engel Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany PubMed articles Google scholar articles
Katharina Koenig Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Martin Peifer Department of Translational Genomics, Centre for Molecular Medicine Cologne, Cologne, Germany PubMed articles Google scholar articles
Erika Mariotti Department of Translational Genomics, Centre for Molecular Medicine Cologne, Cologne, Germany PubMed articles Google scholar articles
Helen Kuenstlinger Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Alexandra Florin Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Ursula Rommerscheidt-Fuss Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Ulrike Koitzsch Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Claudia Wodtke Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Frank Ueckeroth Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Stefanie Holzapfel Institute of Human Genetics, University Hospital Bonn, Bonn, Germany PubMed articles Google scholar articles
Stefan Aretz Institute of Human Genetics, University Hospital Bonn, Bonn, Germany PubMed articles Google scholar articles
Peter Propping Institute of Human Genetics, University Hospital Bonn, Bonn, Germany PubMed articles Google scholar articles
Markus Loeffler Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany PubMed articles Google scholar articles
Sabine Merkelbach-Bruse Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Margarete Odenthal Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Nicolaus Friedrichs Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Lukas Carl Heukamp Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Thomas Zander Department of Internal Medicine I, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles
Reinhard Buettner Institute of Pathology, Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany PubMed articles Google scholar articles

Correspondence to Dr Thomas Zander, Department of Internal Medicine I, Centre for Integrated Oncology, University Hospital Cologne, Kerpenerstr. 62, Cologne 50924, Germany; Thomas.Zander{at}uk-koeln.de

View Full Text

Citation

Kloth M, Ruesseler V, Engel C, et al

Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer

Gut 2016;65:1296-1305.

Publication history

Received December 14, 2014
Revised March 24, 2015
Accepted April 7, 2015
First published April 28, 2015.

Online issue publication

October 26, 2017

Article Versions

Previous version (22 September 2016).
Previous version (26 October 2017).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password